How should I evaluate and manage a patient with suspected Helicobacter pylori infection presenting with dyspepsia, epigastric pain, nausea, or unexplained iron‑deficiency anemia and no alarm features?

Evaluation and Management of Suspected H. pylori Infection

For patients under 45 years without alarm features, proceed directly with non-invasive testing (urea breath test or stool antigen test) followed by 14-day eradication therapy if positive—this "test and treat" strategy is cost-effective and appropriate for primary care management. 1

Initial Risk Stratification by Age and Alarm Features

Age-based approach:

• Patients <45 years without alarm symptoms: Non-invasive testing in primary care is recommended 1
• Patients ≥45 years with severe dyspeptic symptoms: Immediate endoscopy with biopsy is strongly indicated, as gastric malignancy risk increases significantly after age 45 1

Alarm features requiring immediate specialist referral and endoscopy regardless of age: 1

• Anemia (including unexplained iron-deficiency anemia)
• Unintentional weight loss
• Dysphagia
• Palpable abdominal mass
• Malabsorption
• Evidence of gastrointestinal bleeding 1

Non-Invasive Diagnostic Testing

Recommended first-line tests for primary care: 1

• 13C-urea breath test (UBT): Highest accuracy among non-invasive methods
• Stool antigen test: 90-95% accuracy
• Laboratory serology: Only if locally validated

Critical pitfall to avoid: Do not rely on rapid office serological tests due to variable sensitivity and specificity 1

Special Populations Warranting Testing

Test even asymptomatic individuals in these high-risk groups: 1

• Family history of gastric cancer (warrants endoscopy even if <45 years) 1
• First-degree relatives of H. pylori-positive patients (2-3 fold increased risk) 1
• High-risk ethnic groups (Asian, Hispanic, Black, Native American) 1
• Recent immigrants from high gastric cancer incidence regions (Eastern Europe, Andean Latin America, East Asia) 1
• Patients planning chronic NSAID therapy (eradication reduces peptic ulcer risk by 50%) 1

For unexplained iron-deficiency anemia specifically:

• H. pylori testing should be considered as a differential diagnosis in all age groups 2
• Multiple studies demonstrate improvement in ferritin, hemoglobin, and MCV with eradication therapy 2, 3, 4
• H. pylori infection is associated with a 2.6-fold increased prevalence of iron-deficiency anemia 4
• One study showed 91.7% recovery from anemia at 12 months post-eradication 3

Note on conflicting evidence: One 2019 study found no difference in anemia resolution between treated and untreated groups 5, but this contradicts multiple earlier studies and current guideline recommendations that support eradication for unexplained iron-deficiency anemia 1, 6, 2, 3, 4

Treatment Protocol

When H. pylori is confirmed positive:

• Eradication therapy is indicated regardless of symptoms, as infection always implies gastritis and increases risk for peptic ulcer disease and gastric cancer 7
• 14-day regimens are superior to 7-day regimens, achieving >80% eradication rates 6
• Standard regimen: PPI plus two antibiotics for 14 days 7
• Full-dose PPI (e.g., omeprazole 20 mg once daily) taken at the start of meals 1

Post-Treatment Confirmation

Universal test-of-cure is strongly recommended in all treated patients: 6, 7

• Particularly critical in complicated peptic ulcer disease, gastric ulcer, and gastric MALT lymphoma 6
• Timing: No earlier than 4 weeks after treatment cessation 6, 7
• Stop antibiotics, bismuth, or PPIs at least 2 weeks before testing to avoid false-negative results 1, 6, 7
• Preferred methods: 13C-urea breath test or stool antigen test 7

Management of Persistent Symptoms After Confirmed Eradication

If dyspeptic symptoms persist after documented eradication: 1

• Full-dose PPI therapy for predominant epigastric pain
• Prokinetic agents for dysmotility-like dyspepsia

Clinical Benefits of Eradication

Beyond symptom relief, eradication provides: 6

• Prevents peptic ulcer recurrence in >90% of patients with documented ulcer disease
• Cures low-grade gastric MALT lymphoma in 60-80% of early-stage cases
• Reduces gastric cancer risk by halting progression of precancerous lesions
• Treats associated iron-deficiency anemia, idiopathic thrombocytopenic purpura, and vitamin B12 deficiency
• Improves bioavailability of thyroxine and L-dopa